The United States market has seen a positive trend, with a 1.0% increase over the last week and an impressive 18% rise over the past year, while earnings are anticipated to grow by 17% annually in the coming years. In such an environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong internal confidence and alignment of interests between management and shareholders.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Upstart Holdings (UPST) | 13.9% | 66.5% |
| Precigen (PGEN) | 11.7% | 55.4% |
| Nu Holdings (NU) | 22.8% | 20.2% |
| Karman Holdings (KRMN) | 15.4% | 54% |
| Himax Technologies (HIMX) | 29.2% | 70.2% |
| Dave (DAVE) | 17.7% | 22.5% |
| Cerebras Systems (CBRS) | 11% | 73.7% |
| Astera Labs (ALAB) | 10% | 33.2% |
| AppLovin (APP) | 23.3% | 20.6% |
| Almonty Industries (ALM) | 10.8% | 24.2% |
Here's a peek at a few of the choices from the screener.
Esquire Financial Holdings (ESQ)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Esquire Financial Holdings, Inc. is the bank holding company for Esquire Bank, National Association, offering commercial banking products and services to legal and small businesses as well as commercial and retail customers in the United States, with a market cap of approximately $1.56 billion.
Operations: The company's revenue primarily comes from its Community Banking segment, which generated $149.31 million.
Insider Ownership: 11.5%
Earnings Growth Forecast: 60.7% p.a.
Esquire Financial Holdings recently completed a merger with Signature Bancorporation, expanding its board and potentially enhancing strategic direction. Despite substantial insider selling over the past quarter, Esquire's earnings and revenue are forecast to grow significantly faster than the US market at 60.71% and 38.6% per year respectively. However, shareholders have experienced dilution in the past year, which may impact investor sentiment despite strong growth projections.
- Click here to discover the nuances of Esquire Financial Holdings with our detailed analytical future growth report.
- In light of our recent valuation report, it seems possible that Esquire Financial Holdings is trading beyond its estimated value.
Tesla (TSLA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Tesla, Inc. is involved in the design, development, manufacturing, leasing, and sale of electric vehicles as well as energy generation and storage systems globally, with a market capitalization of approximately $1314.45 billion.
Operations: The company's revenue segments include Automotive at $90.82 billion and Energy Generation and Storage at $12.80 billion.
Insider Ownership: 28.5%
Earnings Growth Forecast: 34.3% p.a.
Tesla's earnings are forecast to grow significantly at 34.3% annually, outpacing the US market's growth rate. Despite a recent decline in profit margins and shareholder dilution, Tesla maintains robust insider ownership. Recent strategic moves include partnerships with Zelestra and Verdek to expand energy projects and EV infrastructure, enhancing its growth potential. However, rumors about restructuring its China operations for a merger with SpaceX were denied by Elon Musk, highlighting stability concerns amidst expansion efforts.
- Click to explore a detailed breakdown of our findings in Tesla's earnings growth report.
- The valuation report we've compiled suggests that Tesla's current price could be inflated.
Hinge Health (HNGE)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Hinge Health, Inc. is a company that leverages technology to scale and automate healthcare delivery, with a market cap of $7.18 billion.
Operations: The company's revenue is primarily derived from its Healthcare Software segment, which generated $720.06 million.
Insider Ownership: 17%
Earnings Growth Forecast: 27.1% p.a.
Hinge Health's recent financial performance shows strong growth, with Q2 sales reaching US$212.82 million and a net income of US$43.69 million, a turnaround from last year's loss. The company raised its 2026 revenue guidance to US$856-860 million, reflecting significant growth expectations. Hinge Health's strategic expansion into orthopedic surgery through HingeSelect aims to reduce costs by up to 50%. Despite no recent insider trading activity, the company's buyback plan underscores confidence in its market position.
- Dive into the specifics of Hinge Health here with our thorough growth forecast report.
- Our valuation report here indicates Hinge Health may be undervalued.
Next Steps
- Gain an insight into the universe of 173 Fast Growing US Companies With High Insider Ownership by clicking here.
- Ready For A Different Approach? AI is about to change healthcare. These 131 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com